PT-112

THE CHALLENGE

A minority of patients respond to I-O therapy.

And of those patients, only a small subset experience the promise of long-term benefit.

THE SOLUTION

PT-112 promotes an anti-cancer immune response.

PT-112 inhibits ribosomal biogenesis (RiBi) and selectively kills cancer cells. PT-112’s best-in-class ICD effects stimulate dendritic cells to recruit and activate T-cells to the tumor microenvironment (TME), creating the potential for effective and durable responses. Results from our published non-clinical studies validate this approach.

THE CHALLENGE

Many patients are unable to tolerate anti-cancer therapies due to toxicity.

Chemotherapy, targeted agents, and radiation therapy can have frequent and severe side effects and may compromise quality of life.

THE SOLUTION

PT-112 is a safe small molecule.

Across multiple clinical trials to date, PT-112 — as a single agent and in combination — has been well tolerated in predominantly heavily pre-treated patients.

THE CHALLENGE

There is a need for therapies that effectively treat cancers affecting the bone.

Tumors that originate in or metastasize to the bone are difficult to treat and may cause severe pain. This compromises quality of life and presents a drug development challenge.

THE SOLUTION

PT-112’s osteotropism allows for targeting disease in the bone.

PT-112’s pyrophosphate component has affinity for bone (osteotropism). This provides a rationale for addressing cancers, such as metastatic prostate, lung or breast cancer, and hematological malignancies, such as multiple myeloma.

THE CHALLENGE

Late-stage cancer patients often have limited therapeutic options.

New approaches are needed for those patients who have exhausted available therapies.

THE SOLUTION

PT-112 has a novel mechanism of action with demonstrated activity in late-stage patients.

PT-112, with its immunogenic properties, offers a different approach to treating such patients who have become resistant or refractory to other agents.